How long does a course of giritinib (segatan) need to be taken and protocol analysis

Gilteritinib (Gilteritinib, trade nameXospata) is an oral FLT3 inhibitor, mainly used to treat relapsed or refractory acute myeloid leukemia (R/R AML) patients, especially those carrying FLT3 mutations. As a targeted drug, giritinib can inhibit the activity of FLT3 receptor tyrosine kinase, thereby inhibiting the proliferation of leukemia cells. Its medication regimen and treatment course design are closely related to the patient's condition, type of genetic mutation, and treatment tolerance.

In clinical practice, gilitinib is usually administered orally once daily, with the recommended dose being 120 mg/day. The length of the course of treatment depends on the specific condition of the patient. Generally, administration is continued until the disease progresses or intolerable toxic side effects occur. Compared with traditional chemotherapy, giritinib's oral dosage regimen is more flexible, allowing long-term maintenance treatment in outpatient settings, while reducing the number of hospitalizations and improving patients' quality of life.

For a complete course of treatment, doctors will conduct dynamic assessments based on the patient's hematological indicators, bone marrow examination results and treatment response. If the patient experiences platelet decline, abnormal liver function or other adverse reactions while taking the medication, the dose may need to be adjusted or the medication may be temporarily discontinued. In addition, in combination with chemotherapy or hematopoietic stem cell transplantation, the course of giritinib may be individually adjusted according to the overall treatment plan to maximize efficacy and control toxic side effects.

In general, the treatment course of giritinib is highly individualized and is generally based on daily oral administration of 120 mg until the disease is controlled or intolerable side effects occur. Patients need to regularly monitor hematological and biochemical indicators while taking the medication, and follow the doctor's medication instructions. Through scientific treatment course management and follow-up evaluation, giritinib can provide effective targeted therapy options for patients with FLT3-positive relapsed or refractory AML.

Reference materials:https://www.drugs.com/